UK – Ibrance given NICE green light in breast cancer

Pfizer has announced the National Institute for Health and Care Excellence (NICE) approval of Ibrance (palbociclib), following a final guidance from the organisation.

The potentially life-extending drug will now be available for patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer, who have already had endocrine therapy.

The med, which will be available on the Cancer Drugs Fund (CDF) in combination with fulvestrant, joins two other NICE-approved drugs – (Kisqali) ribociclib and Verzenios (abemaciclib) – as an option at this stage of the treatment pathway.

The recommendation is based on data from the Phase III clinical trial, PALOMA-3, in which Ibrance delayed disease progression by 6.6 months, compared to fulvestrant alone.

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor works by inhibiting proteins in cancer cells, thereby preventing the cells from dividing and growing…